Data Source:
In February 2022, the National Cancer Center issued the "2016 China Cancer Incidence and Death Statistics".





APCS
ANPAC Pan-Cancer Screening
CDA+ct-DNA technology joint test, up to 24 cancers can be screened at one time, pinpoint multiple organs and cancer species.
This package focuses on the detection of cancer-related gene mutations in peripheral free DNA fragments, combining information at the cellular level and protein level, According to Anpac’s own 300,000 test sample database combined with the international universal COSMIC database information, Through the Anpac multi-parameter calculation algorithm processing, early warning of a variety of cancers.
Screening for the early risk signals of 24 common tumors in one go to prevent cancer!
Product Characteristics

variety
Pan-cancer screening, up to 24 cancer types can be screened at one time.

orientation
Can locate multiple organs and cancer species.

expediency
Just take the peripheral blood, no fasting,
Inspection on demand.

immediately
The detection is instantaneous and can reflect the physical condition at the moment of detection.

Ahead of schedule
It has certain foresight and can detect latent lesions in advance.
Pan-Cancer Screening Product Content
It can screen for up to 24 common cancer types at one time and can locate multiple organs. Early detection of latent lesions, timely intervention, cancer prevention!
